Alectinib then targeted radiation for ALK-positive lung cancer
Part of Cancer, Injuries & trauma, Lungs & breathing clinical trials.
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is stage III (not suitable for surgery/chemoradiation) or stage IV, or it came back after surgery and can’t be fully cured with other big treatments
- Your tumor has an ALK rearrangement (a specific genetic change)
- After 2–3 months of alectinib, your cancer is not growing (stable disease) or has shrunk (partial response)
- There are not too many active cancer spots—up to 5 lesions on a PET scan—and the team says all spots can be treated with radiation
- You can take the study treatments safely: you’re generally strong enough (ECOG 0–2), have adequate organ function, and—if lung targets are planned—your lung breathing test (FEV1) is at least 1 liter
- You don’t have certain conditions that raise risk: cancer spreading into the brain’s lining (leptomeningeal disease), fluid buildup from cancer that hasn’t settled after induction, or lung scarring/fibrosis or active non-infectious lung inflammation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies how alectinib (an ALK-blocking medicine) moves through the body and how it’s tolerated in people with advanced non-small cell lung cancer (NSCLC) that has an ALK rearrangement. You may be considered if you have ALK-positive, recurrent or advanced disease and have already had specific prior treatments.
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This trial tests combining the targeted pill alectinib with chemotherapy before the main treatment for stage III ALK-positive lung cancer that can't be removed surgically. The goal is to see if this combo shrinks the tumor and improves outcomes.
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
Hear when a new Radiotherapy Side Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.